1. Home
  2. APLM vs MRNS Comparison

APLM vs MRNS Comparison

Compare APLM & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • MRNS
  • Stock Information
  • Founded
  • APLM 2016
  • MRNS 2003
  • Country
  • APLM United States
  • MRNS United States
  • Employees
  • APLM N/A
  • MRNS N/A
  • Industry
  • APLM Blank Checks
  • MRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • APLM Finance
  • MRNS Health Care
  • Exchange
  • APLM Nasdaq
  • MRNS Nasdaq
  • Market Cap
  • APLM 15.6M
  • MRNS 15.1M
  • IPO Year
  • APLM N/A
  • MRNS 2014
  • Fundamental
  • Price
  • APLM $7.89
  • MRNS $0.24
  • Analyst Decision
  • APLM Strong Buy
  • MRNS Buy
  • Analyst Count
  • APLM 2
  • MRNS 12
  • Target Price
  • APLM $425.00
  • MRNS $4.28
  • AVG Volume (30 Days)
  • APLM 106.0K
  • MRNS 830.0K
  • Earning Date
  • APLM 08-14-2024
  • MRNS 11-12-2024
  • Dividend Yield
  • APLM N/A
  • MRNS N/A
  • EPS Growth
  • APLM N/A
  • MRNS N/A
  • EPS
  • APLM N/A
  • MRNS N/A
  • Revenue
  • APLM $2,101,000.00
  • MRNS $31,466,000.00
  • Revenue This Year
  • APLM N/A
  • MRNS $15.71
  • Revenue Next Year
  • APLM N/A
  • MRNS $40.57
  • P/E Ratio
  • APLM N/A
  • MRNS N/A
  • Revenue Growth
  • APLM 70.54
  • MRNS 1.63
  • 52 Week Low
  • APLM $6.50
  • MRNS $0.23
  • 52 Week High
  • APLM $105.00
  • MRNS $11.26
  • Technical
  • Relative Strength Index (RSI)
  • APLM 42.42
  • MRNS 25.86
  • Support Level
  • APLM $7.70
  • MRNS $0.23
  • Resistance Level
  • APLM $8.88
  • MRNS $0.30
  • Average True Range (ATR)
  • APLM 1.34
  • MRNS 0.02
  • MACD
  • APLM -0.04
  • MRNS 0.02
  • Stochastic Oscillator
  • APLM 24.77
  • MRNS 12.59

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Share on Social Networks: